Cases demonstrate ease-of-use of CGuard™ EPS in two challenging clinical situations physicians face when treating carotid artery disease
TEL AVIV, Israel, Jan. 23, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that two successful live cases featuring CGuard™ EPS were presented at LINC 2019, which is being held January 21 – 23 in Leipzig, Germany.
“The live demonstrations of CGuard™ EPS at this year’s LINC conference, a major international interventional conference covering the latest innovations in vascular medicine, allowed attending physicians to see first-hand the simplicity of the CGuard EPS procedure as conducted by world renowned interventional cardiologists and angiologists,” said Dr. James Barry, President and Chief Executive Officer of InspireMD. “It is immensely gratifying to once again have CGuard™ EPS chosen by these leading interventionalists to be prominently featured in two live case transmissions today at LINC 2019.”
Live case #1: Patient with Symptomatic Left Carotid Artery Disease and Concomitant Coronary Artery Disease
The first live case was conducted by Dr. Antonio Micari and Dr. Fausto Castriota, interventional cardiologists at Humanitas Gavazzeni Hospital, Bergamo, Italy. The patient had stable angina over the prior twelve months, with one hospital admission for one transient ischemic attack (TIA) approximately one month ago. The risk factors included hypertension, hypercholesterolemia and critical left interior carotid artery (LICA) stenosis with evidence of soft plaque. The procedure was successfully performed with the 8mm x 40mm CGuard™ EPS, lasted approximately 20 minutes and had an excellent angiographic result.
Following the procedure, Drs. Micari and Castriota commented, “This patient presented with multiple co-morbidities, including a history of transient ischemic attacks, and a large amount of soft plaque that significantly increases the chance of embolization associated with conventional carotid stents. There were no adverse events during the procedure. At this early stage, it appears that CGuard™ EPS offers superior patient protection where conventional carotid stents may not.”
Live case #2: Restenosis of the Left Common Carotid Artery after TEA
The second live case was conducted by Drs. Andre Schmidt and Matthias Ullrich of Universitaetsklinikum of Leipzig, in Leipzig, Germany. The patient was symptomatic with a high grade stenosis of the right common carotid artery, likely caused by post radiation and open surgery due to a parotid tumor, and had dizziness. The risk factors included hypertension, hyperlipidemia and the patient is a former smoker. The patient received a 8mm x 40mm CGuard™ EPS and the case also lasted approximately 20 minutes with an excellent angiographic result.
Following the procedure, Drs. Schmidt and Ullrich commented, “We were very happy with the performance of the CGuard in today’s challenging case that is not seen in everyday practice. It continues to reinforce our positive impressions of this innovative product and we look forward to continuing to implement it in our practice.”
About LINC
LINC is a leading global forum for new methods in the field of vascular medicine. LINC brings together medical professionals from different specialties around the world who perform endovascular interventions.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes.
InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com